Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
I-Mab Biopharma US Limited is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This portfolio's active prosecution is limited to 1 distinct examiner, which simplifies the coordination of responses and legal strategy. The matter is being processed within 1 distinct art unit, ensuring that the technical review is handled by a specific group of specialists. This concentration of activity allows for a highly specialized approach to the company's intellectual property management.
CESARE, JOSEPH DAVID is identified as the busiest examiner, with 1 pending office action under review. This figure represents the total of 1 pending office action for the company, making this examiner the sole arbiter of the company's current patent applications. Such a concentrated workload allows the applicant to dedicate full attention to the specific procedural nuances of this single examiner. Navigating the requirements of this individual is the primary task for the company's prosecution team at this stage.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CESARE, JOSEPH DAVID | 1 | — | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18270472 | FORMULATIONS OF ANTI-CD73 ANTIBODIES | CESARE, JOSEPH DAVID | 1675 | §103Other | Non-Final OA | 8d overdue | Pending | Jun 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial